ArticleThe Kaohsiung journal of medical sciences2019
MicroRNA-379 inhibits laryngeal carcinoma cell proliferation and invasion through directly targeting TCF-4.
Article in The Kaohsiung journal of medical sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 5 citations in OpenAlex.
- The Role of MicroRNAs Implicated in the Regulation of PI3K/AKT and Focal Adhesion Signaling Pathways in Chronic Obstructive Pulmonary Disease.Biochemical genetics · 2026Article
- Expression of microRNA-379 reduces metastatic spread of prostate cancer.Frontiers in oncology · 2023Article
- MicroRNA-379 inhibits laryngeal carcinoma cell proliferation and invasion through directly targeting TCF-4.The Kaohsiung journal of medical sciences · 2019Article
- miR-26b-5p/TCF-4 Controls the Adipogenic Differentiation of Human Adipose-derived Mesenchymal Stem Cells.Cell transplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The expression pattern, functions, and detailed regulatory mechanisms of miR-379 in laryngeal carcinoma remain unknown. In the present study, we aimed to uncover novel potential miR-379 targets and shed light on its roles in laryngeal carcinoma. The expression level of miR-379 was measured based on the data obtained from the TCGA database and the cell lines. After miR-379 mimic transfection, cell proliferation, invasion and migration assay, and wound-healing assay in HEp-2 cell line were implemented to evaluate the effects of miR-379 on laryngeal carcinoma in vitro. The target genes for miR-379 in silico were predicted and validated using luciferase reporter assay. The miR-379 expression level was reduced in laryngeal carcinoma tissues and cell lines. Moreover, miR-379 overexpression inhibited the cell proliferation, migration, and invasion of laryngeal carcinoma cells. TCF-4 was detected as a direct target of miR-379 in laryngeal carcinoma. Furthermore, restored TCF-4 expression rescued the inhibitory roles of miR-379 overexpression on cell proliferation, migration, and invasion.Our study for the first time demonstrated that miR-379/TCF-4 might involve in the progression of laryngeal carcinoma, and miR-379 appears to serve as a novel tumor suppressor in laryngeal carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.